| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
The primary targets of Timosaponin AIII include the PI3K/Akt, MAPK, and NF-κB signaling pathways. It modulates these pathways, inducing apoptosis, inhibiting proliferation and migration of cancer cells, and exhibiting anti-inflammatory and antioxidant effects. The compound's ability to modulate multiple signaling pathways contributes to its diverse biological activities.
|
|---|---|
| ln Vitro |
Acetylcholinesterase (AChE) activity is inhibited by timosaponin AIII, with an IC50 of 35.4 μM[1]. The primary selective cytotoxic effect of BN108 is thought to be mediated by timosaponin AIII, which also induces ER stress, protective autophagy, and mTOR inhibition [2].
In vitro, Timosaponin AIII has been shown to have anticancer, anti-inflammatory, and antioxidant activities. It modulates the PI3K/Akt, MAPK, and NF-κB signaling pathways, inducing apoptosis and inhibiting proliferation of cancer cells. The compound's biochemical profile includes antioxidant and anti-inflammatory activities. |
| ln Vivo |
Timosaponin AIII (TA3) was the most successful steroidal saponin in addressing memory impairments among those that were examined. Scopolamine-induced step delay reduction was enhanced by timosaponin AIII by 17% (10 mg/kg), 28% (20 mg/kg), and 43% (40 mg/kg). During acquisition trials, no variations in latency were noticed. The efficient inhibition of acetylcholine decrease in the brains of mice treated with scopolamine is achieved by timosaponin AIII (20, 40 mg/kg, po). Timosaponin AIII's inhibitory effect is similar to that of tacrine, which is employed as a positive control [1].
In vivo, Timosaponin AIII has been shown to ameliorate learning and memory deficits in mice. It also exhibits antithrombotic activity. The compound's anti-inflammatory effects have been confirmed in various animal models. However, specific detailed in vivo protocols are limited in the available literature. |
| Enzyme Assay |
In vitro enzyme or receptor binding assays for Timosaponin AIII are not typically performed, as it does not have a single specific target. Its activity is assessed in cell-based assays rather than direct enzyme inhibition studies. The compound's ability to modulate signaling pathways is studied by measuring changes in protein phosphorylation and gene expression.
|
| Cell Assay |
In vitro cell-based assays for Timosaponin AIII are performed using various cancer cell lines. Cells are treated with the compound, and cell viability, proliferation, and apoptosis are assessed using standard assays. The modulation of PI3K/Akt, MAPK, and NF-κB signaling pathways is analyzed by Western blotting.
|
| Animal Protocol |
In vivo animal experiments for Timosaponin AIII are conducted using mouse models. The compound has been shown to ameliorate learning and memory deficits in mice. However, specific detailed protocols for in vivo studies are not well-documented. The compound is typically administered orally or intraperitoneally in preclinical studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Timosaponin AIII indicate that it has a molecular weight of 740.92 and a molecular formula of C39H64O13. It has a melting point of 317-322°C. The compound is soluble in DMSO at ≥60 mg/mL. Powder is stable when stored at -20°C for 3 years or at 4°C for 2 years.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for Timosaponin AIII are limited. As a natural saponin, it is generally considered safe at moderate doses. However, its safety profile in the context of therapeutic use requires further evaluation. The compound is for research use only and not for human therapeutic use.
|
| References |
|
| Additional Infomation |
Timosaponin A-III is a triterpenoid compound. It has the function of a metabolite. Timosaponin A-III has been reported in Narthecium asiaticum, Yucca schidigera, and other organisms with available data.
Other information: Timosaponin AIII is a steroidal saponin isolated from Anemarrhena asphodeloides. It has anticancer, anti-inflammatory, antithrombotic, and nootropic activities. The compound is also known as Timosaponin A-III and Tim-AIII. Its CAS number is 41059-79-4. |
| Molecular Formula |
C39H64O13
|
|---|---|
| Molecular Weight |
740.9177
|
| Exact Mass |
740.434
|
| CAS # |
41059-79-4
|
| PubChem CID |
15953793
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
862.8±65.0 °C at 760 mmHg
|
| Flash Point |
475.6±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.606
|
| LogP |
3.94
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
52
|
| Complexity |
1270
|
| Defined Atom Stereocenter Count |
22
|
| SMILES |
C[C@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)C)OC1
|
| InChi Key |
MMTWXUQMLQGAPC-YXOKLLKRSA-N
|
| InChi Code |
InChI=1S/C39H64O13/c1-18-7-12-39(47-17-18)19(2)28-25(52-39)14-24-22-6-5-20-13-21(8-10-37(20,3)23(22)9-11-38(24,28)4)48-36-34(32(45)30(43)27(16-41)50-36)51-35-33(46)31(44)29(42)26(15-40)49-35/h18-36,40-46H,5-17H2,1-4H3/t18-,19-,20+,21-,22+,23-,24-,25-,26+,27+,28-,29+,30-,31-,32-,33+,34+,35-,36+,37-,38-,39+/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S,16S,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~168.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3497 mL | 6.7484 mL | 13.4967 mL | |
| 5 mM | 0.2699 mL | 1.3497 mL | 2.6993 mL | |
| 10 mM | 0.1350 mL | 0.6748 mL | 1.3497 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
